AI Assistant
Blog
Pricing
Log In
Sign Up
Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
